Stonebridge Financial Group LLC Buys Shares of 36,054 Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Stonebridge Financial Group LLC acquired a new position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 36,054 shares of the company's stock, valued at approximately $286,000.

Other large investors also recently made changes to their positions in the company. JPMorgan Chase & Co. lifted its stake in shares of Amneal Pharmaceuticals by 149.7% during the third quarter. JPMorgan Chase & Co. now owns 1,297,094 shares of the company's stock worth $10,792,000 after purchasing an additional 777,568 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Amneal Pharmaceuticals by 114.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,204,994 shares of the company's stock valued at $10,026,000 after buying an additional 642,065 shares during the period. Geode Capital Management LLC lifted its position in Amneal Pharmaceuticals by 11.1% during the 3rd quarter. Geode Capital Management LLC now owns 3,786,671 shares of the company's stock worth $31,511,000 after acquiring an additional 378,136 shares in the last quarter. Polar Asset Management Partners Inc. boosted its holdings in Amneal Pharmaceuticals by 122.5% in the 3rd quarter. Polar Asset Management Partners Inc. now owns 393,000 shares of the company's stock worth $3,270,000 after acquiring an additional 216,400 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in Amneal Pharmaceuticals by 16.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,404,883 shares of the company's stock valued at $11,689,000 after acquiring an additional 202,863 shares in the last quarter. Institutional investors and hedge funds own 31.82% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on AMRX. StockNews.com downgraded shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Thursday, December 19th. Piper Sandler raised their target price on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an "overweight" rating in a research note on Monday, November 11th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $10.00.

Amneal Pharmaceuticals Price Performance

AMRX traded down $0.18 during trading on Friday, hitting $7.73. The company had a trading volume of 484,881 shares, compared to its average volume of 1,200,624. The company has a market cap of $2.40 billion, a PE ratio of -11.37 and a beta of 1.10. Amneal Pharmaceuticals, Inc. has a 1-year low of $5.01 and a 1-year high of $9.48. The business has a 50-day moving average of $8.06 and a 200-day moving average of $8.25.

Insider Buying and Selling

In other news, Director Gautam Patel sold 80,000 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $8.14, for a total value of $651,200.00. Following the completion of the transaction, the director now owns 1,888,886 shares in the company, valued at approximately $15,375,532.04. This trade represents a 4.06 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders sold 160,000 shares of company stock worth $1,292,000. Corporate insiders own 26.56% of the company's stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.